Ras mutation and compositions and methods related thereto
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/00
C12N-001/16
출원번호
US-0775267
(2010-05-06)
등록번호
US-8470313
(2013-06-25)
발명자
/ 주소
Guo, Zhimin
Lu, Yingnian
Bellgrau, Donald
Franzusoff, Alex
출원인 / 주소
GlobeImmune, Inc.
대리인 / 주소
Sebor, Angela Dallas
인용정보
피인용 횟수 :
7인용 특허 :
13
초록▼
Disclosed are newly discovered Ras mutations and combinations of mutations, proteins and peptides and fusion proteins containing these mutations, nucleic acid molecules encoding such proteins, peptides, and fusion proteins, and a variety of tools and diagnostic, therapeutic, and screening methods as
Disclosed are newly discovered Ras mutations and combinations of mutations, proteins and peptides and fusion proteins containing these mutations, nucleic acid molecules encoding such proteins, peptides, and fusion proteins, and a variety of tools and diagnostic, therapeutic, and screening methods associated with the use of such mutations.
대표청구항▼
1. A composition comprising: a) a whole, heat-killed yeast; andb) a mutated Ras protein comprising at least 11 contiguous amino acids of a wild-type Ras protein having an amino acid sequence of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11 or SEQ ID NO:13 that contains amino acid
1. A composition comprising: a) a whole, heat-killed yeast; andb) a mutated Ras protein comprising at least 11 contiguous amino acids of a wild-type Ras protein having an amino acid sequence of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11 or SEQ ID NO:13 that contains amino acid position 76 with respect to the wild-type Ras protein except that the amino acid at position 76 is mutated as compared to the wild-type Ras protein; wherein the protein is expressed by the yeast. 2. The composition of claim 1, wherein the amino acid at position 76 is mutated from a glutamate to a non-glutamate amino acid residue selected from the group consisting of: glycine, lysine, and glutamine. 3. A composition comprising: a) a yeast vehicle; andb) a protein comprising: (i) a mutant Ras protein or immunogenic domain thereof, wherein the protein or immunogenic domain thereof contains the amino acid position 76 with respect to a wild-type Ras protein, and wherein the amino acid at position 76 is mutated as compared to the wild-type Ras protein; and(ii) at least one additional mutant Ras protein or immunogenic domain thereof, wherein the at least one additional mutant Ras protein or immunogenic domain thereof comprises an amino acid sequence selected from the group consisting of: (a) an amino acid sequence comprising at least from positions 8-16 of a Ras protein, wherein the amino acid residue at position 12 with respect to the wild-type Ras protein is mutated; (b) an amino acid sequence comprising at least from positions 9-17 of a Ras protein, wherein the amino acid residue at position 13 with respect to the wild-type Ras protein is mutated; (c) an amino acid sequence comprising at least from positions 55-63 of a Ras protein, wherein the amino acid residue at position 59 with respect to the wild-type Ras protein is mutated; (d) an amino acid sequence comprising at least from positions 57-65 of a Ras protein, wherein the amino acid residue at position 61 with respect to the wild-type Ras protein is mutated; (e) an amino acid sequence comprising at least from positions 69-77 of a Ras protein, wherein the amino acid residue at position 73 with respect to the wild-type Ras protein is mutated; (f) an amino acid sequence comprising at least from positions 70-78 of a Ras protein, wherein the amino acid residue at position 74 with respect to the wild-type Ras protein is mutated; (g) an amino acid sequence comprising at least from positions 71-79 of a Ras protein, wherein the amino acid residue at position 75 with respect to the wild-type Ras protein is mutated; (h) an amino acid sequence comprising at least from positions 73-81 of a Ras protein, wherein the amino acid residue at position 77 with respect to the wild-type Ras protein is mutated; and (i) an amino acid sequence comprising at least from positions 74-82 of a Ras protein, wherein the amino acid residue at position 78 with respect to the wild-type Ras protein is mutated; wherein the protein is expressed by the yeast vehicle. 4. A composition comprising: a) a yeast vehicle; andb) a protein comprising: (i) a mutant Ras protein or immunogenic domain thereof, wherein the protein or immunogenic domain thereof contains the amino acid position 76 with respect to a wild-type Ras protein, and wherein the amino acid at position 76 is mutated as compared to the wild-type Ras protein; and(ii) a second mutant Ras protein or immunogenic domain thereof, wherein the second protein or immunogenic domain thereof contains the amino acid position 12 with respect to a wild-type Ras protein, and wherein the amino acid at position 12 is mutated as compared to the wild-type Ras protein;wherein the protein is expressed by the yeast vehicle. 5. The composition of claim 4, wherein the amino acid at position 12 is mutated from a glycine to an amino acid selected from the group consisting of valine, cysteine, aspartate, arginine, serine, and alanine. 6. A composition comprising: a) a yeast vehicle; andb) a protein comprising: (i) a mutant Ras protein or immunogenic domain thereof, wherein the protein or immunogenic domain thereof contains the amino acid position 76 with respect to a wild-type Ras protein, and wherein the amino acid at position 76 is mutated as compared to the wild-type Ras protein; and(ii) a second mutant Ras protein or immunogenic domain thereof, wherein the second protein or immunogenic domain thereof contains the amino acid position 13 with respect to a wild-type Ras protein, and wherein the amino acid at position 13 is mutated as compared to the wild-type Ras protein;wherein the protein is expressed by the yeast vehicle. 7. A composition comprising: a) a yeast vehicle; andb) a protein comprising the following proteins, fused in frame: i) a mutant Ras protein or immunogenic domain thereof, wherein the protein or immunogenic domain contains the amino acid position 12 with respect to a wild-type Ras protein, and wherein the glycine at position 12 is substituted with a cysteine;ii) a mutant Ras protein or immunogenic domain thereof, wherein the protein or immunogenic domain contains the amino acid position 61 with respect to a wild-type Ras protein, and wherein the glutamine at position 61 is substituted with an arginine;iii) a mutant Ras protein or immunogenic domain thereof, wherein the protein or immunogenic domain contains the amino acid position 12 with respect to a wild-type Ras protein, and wherein the glycine at position 12 is substituted with an aspartate;iv) a mutant Ras protein or immunogenic domain thereof, wherein the protein or immunogenic domain contains the amino acid position 12 with respect to a wild-type Ras protein, and wherein the glycine at position 12 is substituted with a valine;v) a mutant Ras protein or immunogenic domain thereof, wherein the protein or immunogenic domain contains the amino acid position 12 with respect to a wild-type Ras protein, and wherein the glycine at position 12 is substituted with an arginine; andvi) a mutant Ras protein or immunogenic domain thereof, wherein the protein or immunogenic domain contains the amino acid position 76 with respect to a wild-type Ras protein, and wherein the glutamate at position 76 is substituted with a glycinewherein the protein is expressed by the yeast vehicle. 8. The composition of claim 4, wherein the protein comprises the following proteins, fused in frame: i) a mutant Ras protein or immunogenic domain thereof, wherein the protein or immunogenic domain contains the amino acid position 12 with respect to a wild-type Ras protein, and wherein the glycine at position 12 is substituted with an arginine;ii) a mutant Ras protein or immunogenic domain thereof, wherein the protein or immunogenic domain contains the amino acid position 76 with respect to a wild-type Ras protein, and wherein the glutamate at position 76 is substituted with a glycine. 9. The composition of claim 7, wherein the protein comprises the amino acid sequence of SEQ ID NO:14. 10. The composition of claim 8, wherein the protein comprises the amino acid sequence of SEQ ID NO:15. 11. The composition of claim 3, wherein the protein comprises at least one additional cancer antigen or immunogenic domain thereof. 12. The composition of claim 3, wherein the yeast vehicle is a whole yeast. 13. The composition of claim 12, wherein the whole yeast is killed. 14. The composition of claim 12, wherein the whole yeast is heat-killed. 15. The composition of claim 3, wherein the yeast vehicle is from Saccharomyces. 16. The composition of claim 3, wherein the yeast vehicle is from Saccharomyces cerevisiae. 17. The composition of claim 4, wherein the yeast vehicle is a whole, heat-killed yeast. 18. The composition of claim 4, wherein the yeast vehicle is from Saccharomyces cerevisiae. 19. The composition of claim 7, wherein the yeast vehicle is a whole, heat-killed yeast. 20. The composition of claim 7, wherein the yeast vehicle is from Saccharomyces cerevisiae.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (13)
Hitzeman Ronald A. ; Hagie ; IV Franklin E. ; Hall Benjamin D. ; Ammerer Gustav, Expression of polypeptides in yeast.
Perucho Manuel (Stony Brook NY) Nakano Hirofumi (Port Jefferson Station NY) Yamamoto Fumiichiro (Port Jefferson Station NY) Neville Craig (Miller Place NY), Novel mutation of the c-K-ras oncogene activated in a human lung carcinoma.
Apelian, David; King, Thomas H.; Guo, Zhimin; Coeshott, Claire, Compositions and methods for the treatment or prevention of hepatitis B virus infection.
Apelian, David; King, Thomas H.; Guo, Zhimin; Coeshott, Claire, Compositions and methods for the treatment or prevention of hepatitis B virus infection.
Apelian, David; King, Thomas H.; Guo, Zhimin; Coeshott, Claire, Compositions and methods for the treatment or prevention of hepatitis B virus infection.
Apelian, David; King, Thomas H.; Guo, Zhimin; Coeshott, Claire, Compositions and methods for the treatment or prevention of hepatitis B virus infection.
Selitrennikoff, Claude P.; Miller, Tamara K, Compositions and methods to elicit immune responses against pathogenic organisms using yeast-based vaccines.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.